Australia's Medical Research Funding at Critical Juncture After 90 Years of NHMRC Success
Australia's National Health and Medical Research Council marks 90 years of funding medical breakthroughs while facing warnings that research institutes could exhaust capital within a decade. The NHMRC's success includes funding the HPV vaccine that put Australia on track to eliminate cervical cancer by 2035, but sustained funding is needed to maintain world-class research capabilities.
As Australia marks 90 years of nationally coordinated health and medical research funding, the National Health and Medical Research Council (NHMRC) is celebrating nine significant decades of discovery through to impact while facing warnings that medical research institutes will exhaust their capital within a decade unless funding improves. The NHMRC reflects on how research has changed over time and why it needs to continue evolving to face current and emerging challenges impacting all Australians.
Australia's health system is widely recognised as one of the strongest in the world, underpinned by a long tradition of high quality health and medical research. Over decades, research discoveries have driven major gains in life expectancy, disease prevention and the quality and safety of care. NHMRC's role in funding research discoveries cannot be overlooked, as their impact has been greatly felt across major public health challenges such as immunology, malaria and cardiovascular health.
One of the most powerful recent examples is Australia's progress towards eliminating cervical cancer. Just recently the Australian Government announced the country is on track to achieve elimination by 2035 — an extraordinary public health milestone. Central to this success is NHMRC-funded research led by clinician scientist Emeritus Professor Ian Frazer AC FRS FAA. Together with Doctors Jian Zhou and Xiao-Yi Sun, Professor Frazer developed and patented the technology behind the Human Papillomavirus (HPV) vaccine.
From 1986, and through a number of NHMRC grants, the HPV vaccine (GARDASIL®) was commercialised and by 2007, Australia became the first country in the world to include the HPV vaccine in its National Immunisation Program — protecting generations from HPV infection and reducing the risk of developing cervical cancer. In 2021, the national cervical cancer rate decreased to 6.3 per 100,000, compared to 6.6 per 100,000 in 2020 and for the first time since records began in 1982, there were no cervical cancer cases diagnosed in women under 25 in 2021.
Looking across NHMRC's 90-year history, several strengths stand out. Australia has built a highly respected peer review funding system, strong international research collaborations and a culture of methodological rigour. Investment in early and mid-career researchers has helped sustain capability across disciplines, while long term funding schemes have enabled work that delivers impact over decades rather than funding cycles.
However, Australia's medical research institutes will exhaust their capital within a decade unless funding improves, threatening to destroy the country's world-class research capability and economic potential. As Australia's healthcare system has, and continues to, respond to an ageing population, rising chronic disease and evolving community needs, the role of research has never been more important — as has the role of NHMRC as Australia's leading expert body in health and medical research.
Australia's geography and diversity present unique challenges, highlighting the importance of research that is inclusive and connected to people and place. Aboriginal and Torres Strait Islander peoples, people in rural and remote communities, and those experiencing socioeconomic disadvantage continue to face poorer health outcomes.
The success of the HPV vaccine stands as a compelling example of how sustained investment in research can deliver profound and lasting health benefits. The focus now is on accelerating the journey from evidence to practice, so discoveries reach communities sooner and more equitably. Australia's research community produces world leading science, and the task now is to do better through strengthening the connection between research and practice, supporting sustainable research careers, mentoring the next generation, and ensuring public investment translates evidence into impact.